)
Visual
test
Cosmo Pharmaceuticals
Cosmo Pharmaceuticals (COPN) investor relations material
Cosmo Pharmaceuticals H1 2025 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.H1 2025 earnings summary23 Jul, 2025
Executive summary
H1 2025 revenues reached €51.7 million, with EBITDA at €4.9 million and cash holdings of €133.3 million at period end.
Recurring revenues remained stable at €41.9 million, while project-based revenues declined sharply due to a prior year milestone.
Key pipeline progress includes clinical trials in solid tumors, bile acid diarrhea, and ulcerative colitis, with global expansion of GI Genius™ and Winlevi® ongoing.
ESG initiatives advanced, with upgraded MSCI ESG rating, improved peer ranking, and integration into operations.
Strategic partnerships, notably with Apple and Medtronic, are driving innovation and market reach.
Financial highlights
H1 2025 total revenues were €51.7 million, down 62% year-over-year due to a €92.5 million Medtronic milestone in H1 2024.
Recurring revenues were €41.9 million, down 1% year-over-year; project-based revenues were €9.8 million, down 90%.
EBITDA for H1 2025 was €4.9 million, a 94% decrease from H1 2024.
Cash, equivalents, and investments stood at €133.3 million at June 30, 2025, down from €170.4 million at year-end 2024, with no significant debt.
GI Genius™ recurring revenue grew 128% year-over-year; Winlevi® up 23%; Gastro, CDMO & Other down 21%.
Outlook and guidance
FY 2025 revenue guidance raised to €102–107 million, with recurring revenues expected at €85–90 million.
EBITDA guidance increased to €5.5–7.5 million, up €4.5 million from previous outlook.
Cash and investments projected to remain above €110 million by year-end.
H2 2025 expected to deliver double-digit revenue growth, EMA decision on Winlevi®, and key clinical readouts.
R&D expenses to increase in H2 as phase II programs in bile acid diarrhea and distal ulcerative colitis advance.
What's driving Rifamycin's revenue growth?
Explain the rationale for Vision 2030.
Assess Al regulation impact on operations.
Winlevi EMA confidence update?
GI Genius platform expansion beyond GI?
Solid tumor asset strategy post-Phase I?
Partial view of Summaries dataset, powered by Quartr API
Research faster. Power your platform.
Latest summaries
- TimeTickerHeadlineOpen
- 6 FebJ
Strong growth, digital innovation, and margin expansion drive robust multi-year financial outlook. - 6 Feb004020
Operating profit rose on cost savings and high-value sales, with major US expansion underway. - 6 FebJOUT
Net sales up 31%, gross margin at 36.6%, and net loss narrowed to $3.3 million. - 6 FebPECO
Record 2025 occupancy and 7% Core FFO growth; 2026 targets 5.5% FFO growth and strong acquisitions. - 6 FebPROV
Q2 FY2026 net income rose 65% year-over-year, with higher margins and strong credit quality. - 6 FebNVDA
AI-driven digital twins and accelerated computing are set to revolutionize industrial design and manufacturing. - 6 FebCDP
2025 FFO/share rose 5.8% to $2.72, with strong leasing and investment; 2026 guidance signals more growth. - 6 FebCRI
Q1 2025 saw record revenue, a return to profit, and major new contracts in space technology. - 6 FebCRINet loss widened to 7.5m PLN in H1 2024 as revenue fell and R&D costs remained high.
- 6 FebCRINet loss deepened on lower sales and higher costs, but major new contracts and restructuring are underway.
Next Cosmo Pharmaceuticals earnings date
H2 20259 Mar, 2026
Cosmo Pharmaceuticals
Next Cosmo Pharmaceuticals earnings date
H2 20259 Mar, 2026
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
)
)
Frequently asked questions
Cosmo Pharmaceuticals N.V. is a specialty pharmaceutical company focused on therapies for gastrointestinal diseases and medical devices for endoscopy procedures. The company engages in research, development, manufacturing, and commercialization of drug products and diagnostics. It serves both prescription drug and medical technology markets. The company is headquartered in Dublin, Ireland, and its shares are listed on the SIX.
Quartr provides global coverage of all investor relation material from public companies.
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Yes, the Quartr mobile app is free on both iOS and Android.
Yes. Quartr provides global, industry-leading live coverage of company events such as regular earnings calls, capital markets days, M&A announcements, and investor conferences. Live with zero delays. Just click and listen.
Yes, capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Yes. Follow the companies that matter to you. Get a personalized feed with real-time updates, a tailored earnings calendar, and instant alerts when earnings calls go live.
Yes. Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned, regardless of who's talking.
Explore our global coverage